Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Jones Trading Initiates Coverage On Azora Therapeutics with Buy Rating, Announces Price Target of $14
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member Resignations
Adial Pharmaceuticals Form 13G Shows Coastlands Capital Partners Discloses 9.98% Passive Stake In Co. As Of June 17
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals Acquires Azora Therapeutics In All-Stock Transaction, Enters Concurrent Private Placement To Raise Up To $64M
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.